Home > In process > Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease. > print

001     286094
005     20260413131505.0
024 7 _ |a 10.1016/j.tjpad.2026.100544
|2 doi
024 7 _ |a pmid:41905188
|2 pmid
024 7 _ |a pmc:PMC13054424
|2 pmc
024 7 _ |a 2274-5807
|2 ISSN
024 7 _ |a 2426-0266
|2 ISSN
037 _ _ |a DZNE-2026-00390
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Cetindag, Arda C
|b 0
245 _ _ |a Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
260 _ _ |a [Paris]
|c 2026
|b Elsevier Masson SAS
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1776078471_32195
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Early and accurate detection of Alzheimer's disease (AD) is essential for timely intervention and development of disease-modifying treatments. The DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) provides a deeply phenotyped cohort covering preclinical and early clinical stages, including subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Astrocyte reactivity and its biomarkers, particularly glial fibrillary acidic protein (GFAP), have gained increasing attention in AD research; however, the relationship between GFAP and amyloid in early disease, as well as its potential prognostic value beyond its association with amyloid status, remains insufficiently understood.To evaluate the performance of CSF and plasma GFAP across early disease stages, compare these measures according to amyloid status, and assess the prognostic value of GFAP for clinical progression across diagnostic stages during longitudinal follow-up.This study used data from the multicenter DELCODE cohort in Germany, including participants with available plasma and/or CSF samples and standardized clinical, cognitive, imaging, and biomarker assessments.GFAP concentrations in plasma and CSF were quantified using validated immunoassay platforms. Standard CSF AD biomarkers and ApoE genotype were measured using established assays. Amyloid status was defined by the CSF Aβ42/40 ratio. Longitudinal follow-up occurred annually for up to ∼10 years, with clinical conversion determined according to NIA-AA criteria.Plasma and CSF GFAP increased across the AD continuum, with higher levels in MCI and AD (p < 0.001). Plasma GFAP showed a stronger association with amyloid status than CSF GFAP across all groups. In MCI, plasma GFAP combined with age and ApoE4 yielded an AUC of 0.87. Elevated plasma GFAP predicted increased risk of conversion to MCI (HR = 2.19, p < 0.001; adjusted HR = 1.70, p = 0.0056) and AD dementia (HR = 3.5; adjusted HR = 2.49 both p < 0.001).Plasma GFAP is a sensitive, minimally invasive biomarker with diagnostic relevance for amyloid detection and prognostic relevance for clinical progression in early AD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Blood biomarkers of Alzheimer’s disease
|2 Other
650 _ 7 |a Cerebrospinal fluid (CSF)
|2 Other
650 _ 7 |a Glial fibrillary acidic protein (GFAP)
|2 Other
650 _ 7 |a Mild cognitive impairment
|2 Other
650 _ 7 |a Subjective memory decline
|2 Other
700 1 _ |a Schipke, Carola G
|b 1
700 1 _ |a Esselmann, Hermann
|b 2
700 1 _ |a Kruse, Niels
|b 3
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 4
|u dzne
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 5
|u dzne
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 6
|u dzne
700 1 _ |a Miklitz, Carolin
|0 P:(DE-2719)2810438
|b 7
|u dzne
700 1 _ |a Maier, Franziska
|b 8
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 9
|u dzne
700 1 _ |a Janowitz, Daniel
|0 P:(DE-2719)9002557
|b 10
|u dzne
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 11
700 1 _ |a Stöcklein, Sophia
|0 P:(DE-2719)9003671
|b 12
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 13
|u dzne
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 14
|u dzne
700 1 _ |a Kurz, Carolin
|b 15
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 16
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 17
|u dzne
700 1 _ |a Goerss, Doreen
|0 P:(DE-2719)2812583
|b 18
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 19
|u dzne
700 1 _ |a Sodenkamp, Sebastian
|0 P:(DE-2719)9003152
|b 20
|u dzne
700 1 _ |a Najafpour, Elham
|0 P:(DE-2719)9003689
|b 21
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 22
|u dzne
700 1 _ |a Roeske, Sandra
|0 P:(DE-2719)2810395
|b 23
|u dzne
700 1 _ |a Frommann, Ingo
|0 P:(DE-2719)2810481
|b 24
|u dzne
700 1 _ |a Stark, Melina
|0 P:(DE-2719)9001773
|b 25
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 26
|u dzne
700 1 _ |a Ramirez, Alfredo
|0 P:(DE-2719)2812825
|b 27
|u dzne
700 1 _ |a Kleineidam, Luca
|0 P:(DE-2719)2812139
|b 28
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 29
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 30
|u dzne
700 1 _ |a Gemenetzi, Maria
|0 P:(DE-2719)9002025
|b 31
|u dzne
700 1 _ |a Altenstein, Slawek
|0 P:(DE-2719)2811720
|b 32
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 33
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 34
|u dzne
700 1 _ |a Incesoy, Enise I
|0 P:(DE-2719)9001517
|b 35
|u dzne
700 1 _ |a Butryn, Michaela
|0 P:(DE-2719)9001011
|b 36
|u dzne
700 1 _ |a Bauer, Chris
|0 P:(DE-HGF)0
|b 37
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 38
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 39
|e Last author
|u dzne
773 _ _ |a 10.1016/j.tjpad.2026.100544
|g Vol. 13, no. 5, p. 100544 -
|0 PERI:(DE-600)2782183-3
|n 5
|p 100544
|t The journal of prevention of Alzheimer's disease
|v 13
|y 2026
|x 2274-5807
856 4 _ |u https://pub.dzne.de/record/286094/files/DZNE-2026-00390.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/286094/files/DZNE-2026-00390.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2810438
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811351
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-2719)9002557
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9000543
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 12
|6 P:(DE-2719)9003671
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812234
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2812583
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2000055
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)9003152
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)9003689
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2810395
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2810481
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)9001773
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2812825
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2812139
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)9002025
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2811720
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 34
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 35
|6 P:(DE-2719)9001517
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)9001011
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 38
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2811024
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-05-28T09:11:42Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-05-28T09:11:42Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-05-28T09:11:42Z
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2025-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-11
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 0
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 1
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 2
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 3
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 4
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 5
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 6
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 7
920 1 _ |0 I:(DE-2719)1240005
|k ICRU
|l Core ICRU
|x 8
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 9
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka
|l Neuroinflammation, Biomarker
|x 10
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 11
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 12
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 13
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21